Organovo's fatty liver disease drug meets main goal in mid-stage study [Reuters]
Organovo Holdings, Inc. (ONVO)
NASDAQ:AMEX Investor Relations:
organovo.com/about/contact/investor-relations
Company Research
Source: Reuters
, opens new tab said on Monday its experimental drug to treat a type of fatty liver disease met the main goal in a mid-stage study, sending its shares up nearly 27% in premarket trade. The non-steroidal drug, FXR314, helped significantly reduce liver fat in patients with metabolic function-associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis. FXR314 was also found to be safe and well-tolerated, Organovo said. The company expects to present detailed findings of the study at an upcoming conference. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath Our Standards: The Thomson Reuters Trust Principles. New Tab , opens new tab
Show less
Read more
Impact Snapshot
Event Time:
ONVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONVO alerts
High impacting Organovo Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
ONVO
News
- 3D printing in the medical field: four major applications revolutionising the industry [Yahoo! Finance]Yahoo! Finance
- Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Organovo Holdings, Inc. (NASDAQ: ONVO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel DiseaseGlobeNewswire
ONVO
Sec Filings
- 5/31/24 - Form 10-K
- 5/14/24 - Form 424B4
- 5/13/24 - Form 8-K
- ONVO's page on the SEC website